Kangstem Biotech Co. Ltd
Kangstem Biotech Co., Ltd. a biopharmaceutical company, develops stem cell therapeutic products for rare and incurable diseases. The company's stem cell therapy products include Furestem-AD for treatment of subacute and chronic atopic dermatitis; Furestem-RA to treat rheumatoid arthritis; and Furestem-CD for treatment of active crohn's disease. It also provides stem cell conditioned media, such a… Read more
Kangstem Biotech Co. Ltd (217730) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.059x
Based on the latest financial reports, Kangstem Biotech Co. Ltd (217730) has a cash flow conversion efficiency ratio of -0.059x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-3.81 Billion) by net assets (₩64.83 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Kangstem Biotech Co. Ltd - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Kangstem Biotech Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Kangstem Biotech Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kangstem Biotech Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dongkuk Steel Mill Co Ltd
KO:001230
|
-0.014x |
|
Fecon Foundation Engineering and Underground Construction JSC
VN:FCN
|
0.109x |
|
Sitowise Group Oyj
HE:SITOWS
|
0.162x |
|
Star Holdings
NASDAQ:STHO
|
-0.030x |
|
Fursys
KO:016800
|
0.019x |
|
Empresas Tricot S.A
SN:TRICOT
|
0.102x |
|
Nibe Limited
NSE:NIBE
|
0.202x |
|
Resimac Group Ltd
AU:RMC
|
-0.492x |
Annual Cash Flow Conversion Efficiency for Kangstem Biotech Co. Ltd (2015–2024)
The table below shows the annual cash flow conversion efficiency of Kangstem Biotech Co. Ltd from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩43.18 Billion | ₩-18.99 Billion | -0.440x | -18.65% |
| 2023-12-31 | ₩44.52 Billion | ₩-16.50 Billion | -0.371x | +7.15% |
| 2022-12-31 | ₩47.26 Billion | ₩-18.86 Billion | -0.399x | -59.89% |
| 2021-12-31 | ₩68.07 Billion | ₩-16.99 Billion | -0.250x | +7.92% |
| 2020-12-31 | ₩51.62 Billion | ₩-13.99 Billion | -0.271x | -43.92% |
| 2019-12-31 | ₩70.72 Billion | ₩-13.32 Billion | -0.188x | +21.73% |
| 2018-12-31 | ₩47.69 Billion | ₩-11.48 Billion | -0.241x | +46.94% |
| 2017-12-31 | ₩23.47 Billion | ₩-10.65 Billion | -0.454x | -33.67% |
| 2016-12-31 | ₩22.98 Billion | ₩-7.80 Billion | -0.339x | -89.64% |
| 2015-12-31 | ₩21.24 Billion | ₩-3.80 Billion | -0.179x | -- |